A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: BIOLOGICAL: PDR001|BIOLOGICAL: ACZ885|BIOLOGICAL: CJM112|DRUG: TMT212|DRUG: EGF816
Sponsor: Novartis Pharmaceuticals